Market Newsdesk

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) — SueWallSt alerts investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action on behalf of purchasers of Aardvark securities between February 13, 2025 and May 14, 2026, and purchasers in or traceable to the Company’s February 2025 initial public offering. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

AARD shares were sold to the public at $16.00 per share and closed at $4.57 on May 15, 2026, a decline of $11.43 per share, or approximately 71.4%, from the offering price. To be considered for lead plaintiff, investors must file by October 13, 2026.

The Named Individual Defendants

The action names Tien-Li Lee, M.D., Chief Executive Officer and director at all relevant times; Nelson Sun, Chief Financial Officer at all relevant times and Chief Operating Officer since February 9, 2026; and Bryan Jones, Ph.D., who served as Chief Operating Officer until February 9, 2026. The pleading asserts that Lee and Sun signed or authorized the signing of the Registration Statement filed with the SEC in connection with the IPO.

Alleged Control Person Liability

• Each individual defendant allegedly possessed the power and authority to control the contents of Aardvark’s SEC filings, press releases, and investor communications.
• The complaint charges that these officers received the challenged filings and releases before or shortly after issuance and had the ability to prevent or correct them.
• The action alleges the officers had access to material information about ARD-101’s safety profile that was not available to public investors.
• Claims are asserted under Section 20(a) of the Exchange Act and Section 15 of the Securities Act, which reach individuals alleged to have controlled the primary violator.
• As averred, the officers are alleged to be personally liable for representations describing ARD-101 as approximately 99% gut-restricted, with limited systemic absorption and no serious adverse events.

Sarbanes-Oxley Certification Obligations

Senior officers who certify periodic reports attest to the accuracy of those disclosures. The complaint charges that the certifications accompanying Aardvark’s filings were inaccurate because ARD-101 was allegedly less safe than investors were led to believe, and its clinical, regulatory, and commercial prospects were overstated.

“Corporate officers have a duty to ensure their companies’ public statements are accurate and complete. Here, the complaint contends that senior Aardvark officers controlled representations about ARD-101’s safety profile that preceded a voluntary Phase 3 pause and a full FDA clinical hold.” — Joseph E. Levi, Esq.

Submit your information here or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the AARD Lawsuit

Q: Who are the defendants named in the AARD lawsuit? A: The complaint names Aardvark Therapeutics, Inc. and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.

Q: What court was the AARD class action filed in? A: The case was filed in the United States District Court for the Southern District of California, governed by the Private Securities Litigation Reform Act of 1995.

Q: What specific misstatements does the AARD lawsuit allege? A: The complaint alleges Aardvark Therapeutics made materially false or misleading statements regarding the safety and tolerability of ARD-101, including claims that it was approximately 99% gut-restricted with limited systemic absorption and no serious adverse events, during the Class Period. When the voluntary pause of the Phase 3 HERO trial and the FDA’s full clinical hold were disclosed, the stock price declined sharply.

Q: What do AARD investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my AARD shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) — SueWallSt notifies institutional investors in AEVEX Corp. (NYSE: AVEX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between April 17, 2026 and June 4, 2026. Find out if you qualify to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

AEVEX Class A shares fell approximately 16% on June 2, 2026, wiping out more than $700 million in market capitalization, then declined a further 7% on June 5, 2026, erasing roughly $200 million more. Combined, the two sessions are associated with approximately $900 million in lost market value. To be considered for lead plaintiff, investors must file by October 20, 2026.

Notice to Institutional Holders

Funds that acquired AVEX in or traceable to the April 2026 initial public offering may hold among the largest documented positions in the proposed class and sub-class. The pleading asserts that offering documents represented a 180-day lock-up barring the controlling private equity holder from selling until October 13, 2026, while a plan to waive that restriction was allegedly already in place. As averred, the waiver came 41 days after the IPO, clearing the way for a secondary offering of 8,000,000 shares priced at $27.00 per share.

Portfolio Impact Assessment

• Class period exposure: purchases from April 17, 2026 through June 4, 2026, plus shares traceable to the IPO offering documents.
• Two-step decline: 16% on June 2, 2026 and 7% on June 5, 2026, roughly $900 million in aggregate market value.
• Secondary offering net proceeds of $207.9 million allegedly flowed entirely to the controlling stockholder, with the Company receiving nothing.
• Underwriters allegedly shared $8.1 million in additional fees on the secondary offering, following more than $22 million on the $346 million IPO.
• Claims are pleaded under Securities Act Sections 11, 12 and 15 and Exchange Act Sections 10(b) and 20(a).
• Funds with large IPO allocations may face internal review obligations regarding monitoring and preservation of claims.

“Institutional investors play a critical role in securities class actions, and funds with substantial IPO allocations in AEVEX are often best positioned to evaluate the alleged lock-up disclosures at issue here,” — Joseph E. Levi, Esq.

Fiduciary Considerations for Advisers and Trustees

Investment managers, trustees, and plan fiduciaries may have policies requiring documentation of loss exposure and an assessment of whether to seek an active role in pending securities litigation. Loss review is available at no cost and does not obligate a fund to seek appointment.

Learn more about the case and your options or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the AVEX Lawsuit

Q: Who is eligible to join the AVEX investor lawsuit? A: Investors who purchased AVEX stock or securities between April 17, 2026 and June 4, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What specific misstatements does the AVEX lawsuit allege? A: The complaint alleges AEVEX Corp. made materially false or misleading statements regarding the permanence of the 180-day IPO lock-up restricting its controlling stockholder during the Class Period. When the secondary offering filings disclosed that underwriters had agreed to waive those lock-up restrictions, the stock price declined sharply.

Q: What court was the AVEX class action filed in? A: The case was filed in the United States District Court for the Southern District of California, governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential eligibility.

Q: What if I already sold my AVEX shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

Completed Installation of the First Phase of a Planned Rollout Across Cemex Germany’s Truck Fleet
Further Expands SaverOne’s European Footprint

Petah Tikvah, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company specializing in radio frequency (RF)-based solutions for the advanced transportation safety, defense and homeland security markets, today announced the successful completion of installations in Cemex’s trucks in Germany, equipping part of their truck fleet with SaverOne’s Driver Distraction Prevention System (DDPS). The installation represents the first phase of a planned rollout across Cemex Germany’s full truck fleet and follows the successful deployment of SaverOne’s system in Cemex Germany’s passenger cars, as previously announced in 2025. The successful completion of this phase is a step in both Cemex’s and SaverOne’s mutual intention to expand the installation of these systems throughout Cemex’s fleets globally. For SaverOne, it represents another key expansion of its European footprint.

Trucks operate for extended hours on both highways and dense urban routes, where the consequences of driver distraction are particularly severe, and the extension of the DDPS to Cemex Germany’s trucks follows the positive results achieved to date across Cemex’s fleets in Europe. SaverOne and Cemex intend to advance to the enrollment of the system across the remainder of Cemex’s German truck fleet, and aim to advance new deployments across additional Cemex regions and other global work-truck fleets.

Mr. Ori Gilboa, CEO of SaverOne, stated, “Completing this first phase of installations in Cemex Germany’s trucks is an important vote of confidence in our technology and in the results we have delivered to date. Heavy commercial fleets are a core target market for us and already account for the majority of our installations with Cemex, and this phase opens the door to further similar opportunities across their global operations. This is another step in the continued expansion of our footprint in Europe, and it aligns with our strategy of deepening relationships with large multinational customers operating global fleets.”

Michal Padusinsky, Director Supply Chain Czechia, Germany & Poland at Cemex, said, “Driver safety is a critical component of our operational excellence. Having seen the value of SaverOne’s solution in our truck fleets elsewhere in Europe and across our cars in Germany, extending it to our German trucks is a natural next step in reducing distraction-related risks and strengthening safety standards throughout our operations.”

About Cemex

Cemex is an industry leading global construction materials and solutions company that is building a better future safely through more sustainable products and solutions. Cemex is committed to achieving carbon neutrality through relentless innovation and industry-leading research and development. Cemex is at the forefront of the circular economy in the construction value chain and is pioneering ways to increase the use of waste and residues as alternative raw materials and fuels in its operations with the use of new technologies.

Cemex offers cement, ready-mix concrete, aggregates, and urbanisation solutions in growing markets around the world, powered by a multinational workforce focused on providing a superior customer experience, enabled by digital technologies.

For more information please visit: www.cemex.com

About SaverOne

SaverOne is a technology company specializing in RF-based solutions for the advanced transportation safety, defense and homeland security markets. SaverOne designs, develops and commercializes OEM and aftermarket technologies that detect, locate and analyze cellphone RF signals using proprietary hardware, software, AI and algorithms.

SaverOne’s first commercial product line is designed to prevent vehicle accidents caused by driver distraction from mobile phone use. Building on the same core RF sensing platform, SaverOne is also developing solutions for vulnerable road user (VRU) detection under limited-visibility and non-line-of-sight conditions, based on the cellphone footprint of pedestrians and other road users.

In 2026, SaverOne expanded the potential applications of its RF sensing technology beyond transportation through its strategic transaction with VisionWave Holdings, Inc. (Nasdaq: VWAV), focused on integrating SaverOne’s RF capabilities into defense, homeland security and critical infrastructure applications.

Learn more at https://saver.one/

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws that are subject to substantial risks and uncertainties. All statements, besides those of historical fact, contained in this press release are forward-looking. Forward-looking statements contained in this press release include but are not limited to, statements regarding SaverOne’s strategic and business plans, technology, relationships, objectives, and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations, and financial performance and condition and may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions. However, not all forward-looking statements contain these words. Forward-looking statements are based on SaverOne’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions about future events that may not prove accurate. Many factors could cause SaverOne’s actual activities or results to differ materially from those anticipated in such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the ability of our technology to substantially improve the safety of drivers; our ability to protect our patented technology from infringement by third parties; SaverOne’s planned level of revenues and capital expenditures and its ability to continue as a going concern; SaverOne’s ability to maintain its listing on the Nasdaq Capital Market; the ability of SaverOne’s technology to substantially improve the safety of drivers; its ability to market and sell its products; its plans to continue to invest in research and development to develop technology for both existing and new products; SaverOne’s intention to advance its technologies and commercialization efforts in Europe and globally; acceptance of its business model by investors; the ability to correctly identify and enter new markets; the impact of competition and new technologies; general market, political and economic conditions in the countries in which SaverOne operates; projected capital expenditures and liquidity; SaverOne’s intention to retain key employees, and its belief that it will maintain good relations with all employees; as well as other risks and uncertainties, including, but not limited to, the risks detailed in SaverOne’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 27, 2026  and in subsequent filings with the SEC. Forward-looking statements in this announcement are made as of this date, and SaverOne undertakes no duty to update such information except as required under applicable law.

  

International Investor Relations Contact:

Ehud Helft
+1 212 378 8040
[email protected]

ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against Baidu, Inc. (“Baidu”) (NASDAQ: BIDU). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts including allegations that: (1) Baidu had overstated the ability of its AI business to mitigate rapid declines in its legacy online marketing business; (2) as a result, Baidu’s revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants’ positive statements about Baidu’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased Baidu shares between November 18, 2025 and August 17, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. At [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/baidu/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is November 13, 2026. 

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) — SueWallSt notifies investors in Alibaba Group Holding Limited (NYSE: BABA) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between June 26, 2025 and June 24, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

BABA American Depositary Shares traded as high as $173.68 on October 9, 2025 and closed at $95.07 on June 25, 2026, a decline of $78.61 per share, or approximately 45.26%. Shares fell $4.69, or roughly 3.9%, over two trading days ending June 10, 2026, following the U.S. Department of Defense’s updated list of Chinese military companies.

The Alleged NDAA Classification Disclosure Failure

The National Defense Authorization Act for fiscal year 2025 defines a “Chinese military company” to include any entity directly or indirectly controlled by or affiliated with the Chinese Ministry of Industry and Information Technology. According to the lawsuit, Alibaba’s own annual report disclosures acknowledged that its online and mobile commerce operations require an MIIT operating license, yet the Company allegedly never warned shareholders that this affiliation could place it within the statutory definition.

Key NDAA Classification Allegations for Shareholders

• The complaint alleges that entities affiliated with the MIIT fell within the FY2025 NDAA definition of a Chinese military company under Section 1260H(g)(2).
• The lawsuit contends Alibaba was directly or indirectly affiliated with the MIIT through its telecommunications licensing requirements.
• Class Period risk disclosures allegedly identified other Chinese issuers delisted from the NYSE over military-ownership designations, while omitting the Company’s own exposure.
• On June 8, 2026, after market hours, the Department of Defense published an updated list of Chinese military companies that included Alibaba.
• The lawsuit contends that the resulting price decline reflected the correction of prior alleged misstatements and omissions.

“This case presents important questions about disclosure obligations in the technology sector when a company’s own regulatory relationships may trigger U.S. national security designations. The complaint alleges shareholders were told about designation risks facing peer companies while the Company’s own alleged exposure went undisclosed.” — Joseph E. Levi, Esq.

Why the Designation Allegedly Mattered to Investors

U.S. executive orders since 2020 have restricted investment by U.S. persons in publicly traded securities of certain Chinese issuers deemed owned or controlled by the Chinese military. The complaint alleges that this regulatory framework made the Company’s potential status a material fact for anyone purchasing BABA securities during the Class Period.

Submit your information here
or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the BABA Lawsuit

Q: What is the BABA class action lawsuit about? A: A securities class action has been filed against Alibaba Group Holding Limited (NYSE: BABA) alleging materially false and misleading statements between June 26, 2025 and June 24, 2026. Shares fell approximately 45.26% from their Class Period high after disclosures regarding Alibaba’s inclusion on the U.S. Department of Defense list of Chinese military companies and allegations that it illicitly accessed Anthropic’s Claude AI model. Investors who purchased shares during the Class Period and suffered losses may be eligible to seek compensation.

Q: Who is eligible to join the BABA investor lawsuit? A: Investors who purchased BABA stock or securities between June 26, 2025 and June 24, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: What specific misstatements does the BABA lawsuit allege? A: The complaint alleges Alibaba made materially false or misleading statements regarding its affiliation with the Chinese Ministry of Industry and Information Technology and its AI development practices, including characterizing unauthorized distillation of third-party models as hypothetical or inadvertent.

Q: What do BABA investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my BABA shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis, with no retainer and no out-of-pocket costs. Any attorneys’ fees and expenses awarded to class counsel are subject to court approval.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

Applications to serve as lead plaintiff must be filed by October 5, 2026.

CONTACT
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) — SueWallSt notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) that a securities class action has been filed on behalf of shareholders who purchased securities between December 17, 2025 and July 26, 2026. Submit your information now. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

CAPR fell from $19.70 on July 24, 2026, to $4.19, a decline of approximately 78.7%, with an aggregate corrective-disclosure loss of $15.08 per share. The stock dropped $12.70 (64%) to $7.00 on July 27, 2026, then $2.38 (36%) on July 30, 2026. The lead plaintiff deadline is September 28, 2026.

What the Company Told Regulators and Investors

After receiving a July 2025 Complete Response Letter stating the application “does not meet the statutory requirement for substantial evidence of effectiveness,” Capricor announced in March 2026 that the FDA had lifted the CRL, classified the filing as a Class 2 resubmission, and set a PDUFA target action date of August 22, 2026. SEC filings and press releases described HOPE-3 as having met its primary endpoint (p=0.03) and key secondary cardiac endpoint (p=0.04), with the Company adding that the FDA “has not identified any potential review issues.”

Disclosure Gaps Alleged in the Regulatory Narrative

• The complaint challenges the omission that changes were made to the pre-specified statistical analysis plan, generating at least two additional versions after the double-blind portion concluded.
• FDA briefing documents stated the final SAP (v. 3.0), dated November 24, 2025, “was not submitted to FDA for review prior to BLA submission and was not discussed and consequently not agreed upon.”
• The final SAP was allegedly created one day before the data was unblinded.
• Briefing documents indicated the process for SAP changes in the study’s pre-specified blinding plan was not followed, and that Protocol 9.0 deviated from SAP v. 3.0.
• The FDA stated it “does not consider the conversion of raw change to percent change and then back to raw change to have been scientifically justified.”
• Hypersensitivity reactions in 42% of treated patients versus 15% of placebo patients allegedly raised the possibility of functional unblinding.

The FDA characterized the resulting analyses as “post-hoc and exploratory” and wrote that “the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness.” On July 29, 2026, an advisory committee voted 9-3 that available evidence does not support efficacy for DMD-associated cardiomyopathy.

“Generic risk factor language cannot substitute for disclosing specific, known problems already affecting a company’s regulatory position. The complaint alleges investors were not told that the analytical plan underlying the reported HOPE-3 results had not been agreed upon with the FDA.” — Joseph E. Levi, Esq.

Find out if you might qualify to recover losses
or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the CAPR Lawsuit

Q: What specific misstatements does the CAPR lawsuit allege? A: The complaint alleges Capricor Therapeutics made materially false or misleading statements regarding the pre-specified statistical analysis plan for HOPE-3, FDA agreement with changes to that plan, and the resulting risk to regulatory approval of Deramiocel. When the FDA briefing documents and advisory committee outcome were disclosed, the stock price declined sharply.

Q: What court was the CAPR class action filed in? A: The case was filed in the United States District Court for the Southern District of California, governed by the Private Securities Litigation Reform Act of 1995.

Q: Who are the defendants named in the CAPR lawsuit? A: The complaint names Capricor Therapeutics, Inc. and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.

Q: What do CAPR investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt, a brand of Levi & Korsinsky LLP, for a no-cost, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential eligibility.

Q: What if I already sold my CAPR shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis. No upfront fees, no retainer, and no out-of-pocket costs. Any attorneys’ fees and expenses awarded to class counsel are subject to court approval.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) — SueWallSt notifies investors in Primoris Services Corporation (NYSE: PRIM) that a securities class action has been filed on behalf of shareholders who purchased PRIM securities between August 5, 2025 and June 22, 2026. Find out if you could qualify to recover your per-share losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

PRIM fell $23.39 per share, or 21.6%, from $108.34 to $84.95 after the Company announced an internal review identifying substantial challenges, cost overruns, and project delays affecting six renewable energy projects. The lead plaintiff deadline is September 21, 2026.

Jeremy Kinch’s Alleged Role During the Class Period

The complaint identifies Jeremy Kinch as Primoris’ Chief Operations Officer throughout the Class Period until his departure on June 22, 2026. As named in the action, Kinch allegedly participated in market communications concerning Primoris’ renewable energy project execution, bidding discipline, and ability to manage project risk.

The lawsuit contends that these representations were materially misleading because Primoris’ estimating, cost-to-complete forecasting, and project oversight processes were allegedly deficient for significant fixed-price renewable energy projects.

COO Oversight Allegations Tied to Six Projects

The complaint focuses on Kinch’s role as Chief Operating Officer during a period when project execution, estimating and cost controls were central to PRIM’s earnings outlook:

• Kinch allegedly described Primoris’ project selection and execution practices as disciplined and risk aware.
• The action claims Primoris lacked reliable processes for estimating total costs on certain fixed-price renewable projects.
• Plaintiffs allege the Company delayed recognizing cost overruns and margin deterioration.
• Six renewable energy projects allegedly became a principal driver of Primoris’ June 2026 guidance reduction.
• Kinch’s resignation was announced alongside the June 22, 2026 business update.

Accountability Allegations for PRIM Shareholders

The securities action asserts claims under the Exchange Act, including allegations that individual defendants exercised control over Primoris’ public statements and financial disclosures. For shareholders, the key issue is whether operational assurances allegedly attributed to Kinch and others understated known project-cost risks before PRIM shares declined.

“Individual officers who speak to investors about project execution and risk controls may bear responsibility when those statements are alleged to omit material operational problems,” said Joseph E. Levi, Esq. “”Here, the complaint links the COO role to allegations involving six renewable projects, the June 2026 guidance reset, and a $23.39 per-share decline.”

Submit your information here or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the PRIM Lawsuit

Q: What is the PRIM class action lawsuit about? A: A securities class action has been filed against Primoris Services Corporation (NYSE: PRIM) alleging materially false and misleading statements between August 5, 2025 and June 22, 2026. Shares fell approximately 21.6% after the Company disclosed substantial challenges, cost overruns, and project delays affecting six renewable energy projects.

Q: Who is eligible to participate in the PRIM investor lawsuit? A: Investors who purchased PRIM stock or securities between August 5, 2025 and June 22, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether the shares are still held.

Q: How much did PRIM stock drop? A: Shares fell approximately 21.6%, a decline of $23.39 per share, after Primoris announced an internal review and sharply reduced 2026 guidance.

Q: What specific misstatements does the PRIM lawsuit allege? A: The complaint alleges Primoris made materially false or misleading statements regarding disciplined bidding, estimating processes, project controls, cost forecasting, and financial guidance tied to fixed-price renewable energy projects.

Q: What court was the PRIM class action filed in? A: The case was filed in the United States District Court for the Northern District of Texas, Dallas Division, and asserts claims under the federal securities laws.

Q: Who are the defendants named in the PRIM lawsuit? A: The complaint names Primoris Services Corporation and individual defendants including senior executives who allegedly made public statements, signed SEC filings, or were responsible for corporate disclosures during the Class Period.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the class. Lead plaintiffs are typically investors with significant documented losses and provide oversight of the litigation on behalf of all class members.

Q: What if I already sold my PRIM shares, can I still recover losses? A: Yes. Eligibility is based on when shares were purchased and whether losses were suffered, not on whether the shares are still held.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

MALVERN, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc. (NYSE: VSH) today introduced four new series of surface-mount standard rectifiers that are the industry’s first such devices in the low profile DFN6546A package with wettable flanks. Providing space-saving solutions for power line polarity protection and rail to rail protection in commercial, industrial, and automotive applications, the 5 A SE50N6x, 8 A SE80N6x, 10 A SE100N6x, and 12 A SE120N6x are each available with reverse voltages of 200 V, 400 V, and 600 V, and are offered in AEC-Q101 qualified versions.

The latest package in Vishay’s new Power DFN family, the DFN6546A features a compact 6.5 mm by 4.6 mm footprint and an extremely low typical height of 0.88 mm, allowing the Vishay General Semiconductor rectifiers released today to make more efficient use of PCB space. At the same time, the devices’ advanced construction and die placement technology allow for a higher copper content and larger chip sizes, resulting in improved thermal performance, higher current ratings, and forward surge current capability. Compared to solutions in the SMPC (TO-277A) package with the same footprint, the SE50N6x, SE80N6x, SE100N6x, and SE120N6x deliver a 10 % lower profile, 20 % higher current ratings, and 82 % higher forward surge capability.

Featuring an oxide planar chip junction design, the rectifiers offer typical reverse leakage current less than 0.1 μA, while their low forward voltage drops down to 0.77 V reduces power losses to improve efficiency. The devices operate over a wide temperature range from -55 °C to +175 °C, and provide ESD capability in compliance with IEC 61000-4-2, air discharge mode. The wettable flanks of their DFN6546A package allow for automatic optical inspection (AOI), eliminating the need for an X-ray inspection. Ideal for automated placement, the rectifiers offer an MSL moisture sensitivity level of 1, per J-STD-020, LF maximum peak of 260 °C. The devices are RoHS-compliant and halogen-free.

Device Specification Table:

Samples and production quantities of the new surface-mount standard rectifiers in the DFN6546A package are available now, with lead times of eight weeks.

Vishay manufactures one of the world’s largest portfolios of discrete semiconductors and passive electronic components that are essential to innovative designs in the automotive, industrial, computing, consumer, telecommunications, military, aerospace, and medical markets. Serving customers worldwide, Vishay is The DNA of tech.^® Vishay Intertechnology, Inc. is a Fortune 1000 Company listed on the NYSE (VSH). More on Vishay at www.Vishay.com.

The DNA of tech
^® is a registered trademark of Vishay Intertechnology, Inc.

Vishay on Facebook:
http://www.facebook.com/VishayIntertechnology

Vishay Twitter feed:
http://twitter.com/vishayindust

Links to product datasheets:

http://www.vishay.com/ppg?98743 (SE50N6D, SE50N6G, SE50N6J)
http://www.vishay.com/ppg?98744 (SE80N6D, SE80N6G, SE80N6J)
http://www.vishay.com/ppg?98727 (SE100N6D, SE100N6G, SE100N6J)
http://www.vishay.com/ppg?98745 (SE120N6D, SE120N6G, SE120N6J)

Link to product photo:

https://www.flickr.com/photos/vishay/albums/72177720335563596

For more information please contact:

Vishay Intertechnology
Peter Henrici, +1 408 567-8400
[email protected]
or
Redpines
Bob Decker, +1 415 409-0233
[email protected]

LAFOX, Ill., Sept. 15, 2026 (GLOBE NEWSWIRE) — Richardson Electronics, Ltd. (NASDAQ: RELL), a global provider of engineered solutions for the green energy, power management, and custom display markets, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 2:00 p.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/vdG7YOZxaAm. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×[email protected] or register for the event at https://lythampartners.com/fall2026invreg/.   

About Richardson Electronics, Ltd
.

Richardson Electronics, Ltd. is a leading global manufacturer of engineered solutions, green energy products, power grid and microwave tubes, and related consumables; power conversion and RF and microwave components including green energy solutions; tubes for diagnostic imaging equipment; and customized display solutions. More than 55% of our products are manufactured in LaFox, Illinois, Marlborough, Massachusetts, or Donaueschingen, Germany, or by one of our manufacturing partners throughout the world. All our partners manufacture to our strict specifications and per our Supplier Code of Conduct. We serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. The Company’s strategy is to provide specialized technical expertise and “engineered solutions” based on our core engineering and manufacturing capabilities. The Company provides solutions and adds value through design-in support, systems integration, prototype design and manufacturing, testing, logistics, and aftermarket technical service and repair through its global infrastructure. More information is available at www.rell.com. Richardson Electronics’ common stock trades on the NASDAQ Global Select Market under the ticker symbol RELL.

Forward-Looking Statements

This release includes certain “forward-looking” statements as defined by the Securities and Exchange Commission. Statements in this press release regarding the Company’s business that are not historical facts represent “forward-looking” statements that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Item 1A, “Risk Factors” in the Company’s Annual Report on Form 10-K filed on August 3, 2026, and other reports we file with the Securities and Exchange Commission. The Company assumes no responsibility to update the “forward-looking” statements in this release as a result of new information, future events or otherwise.

Contact Information:
Wendy Diddell
Chief Operating Officer
Richardson Electronics, Ltd.
630.208.2323 | [email protected] | rell.com